Table 4. Clinical and immunocytochemical findings in 14 neuroblastomas.
| Clinical outcome |
ICC findings |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case no. | Age | Sex | Stage | N-myc | NSE | HVA | VMA | DA | Years | NED | AWD | DWD | DOD | NESP55 | CgA |
| 41 | <1 | M | 1 | ND | ND | 56 | 35 | ND | 12 | X | 0 | 0 | 0 | — | 3+ |
| 42 | <1 | M | 2B | — | 14 | 95 | 112 | 430 | 5 | X | 0 | 0 | 0 | — | 3+ |
| 43 | <1 | F | 2B | >10 | 13 | 30 | 19 | 1358 | 5 | X | 0 | 0 | 0 | +1 | 3+ |
| 44 | 3 | M | 3 | >10 | 210 | 180 | 51 | 40 079 | 2 | 0 | 0 | 0 | X | +1 | 3+ |
| 45 | 3 | F | 3 | ND | ND | 150 | 47 | 41 608 | 1 | 0 | 0 | 0 | X | +1 | 3+ |
| 46 | 2 | F | 3 | ND | ND | 36 | 6.9 | ND | 9 | X | 0 | 0 | 0 | +1 | 3+ |
| 47 | 1 | F | 3 | ND | ND | 440 | 343 | 9277 | 8 | X | 0 | 0 | 0 | +1 | 3+ |
| 48 | 1 | F | 3 | ND | 68 | 130 | 300 | ND | 14 | X | 0 | 0 | 0 | +2 | 3+ |
| 49 | 4 | M | 4 | >70 | ND | 3.7 | 13 | ND | 1 | 0 | 0 | 0 | X | — | 2+ |
| 50 | 2 | F | 4 | — | 200 | 87 | 6.2 | ND | 1 | 0 | 0 | 0 | X | — | 3+ |
| 51 | 1 | M | 4 | ND | ND | 85 | 14 | ND | 2 | 0 | 0 | 0 | X | — | 3+ |
| 52 | <1 | F | 4 | >10 | 12 | 17 | 15 | 1665 | 12 | X | 0 | 0 | 0 | — | 3+ |
| 53 | 5 | M | 4 | — | 270 | 30 | 17 | 2454 | 1 | 0 | 0 | 0 | X | +1 | 3+ |
| 54 | 3 | M | 4 | ND | ND | 318 | 498 | ND | 3 | 0 | 0 | 0 | X | — | 3+ |
Age=age at diagnosis . F=female, M=male. Stage according to the International Neuroblastoma Staging System (INSS). N-myc=amplification of N-myc gene. NSE=neuron-specific enolase. HVA=homovanillic acid. VMA=vanillylmandelic acid. DA=dopamine. Years=observation time. X indicates outcome at follow up, which was categorized as NED=alive, no evidence of disease. AWD=alive with disease. DWD=Dead with disease. DOD=dead of disease. ICC findings: The categories were as follows: 0=<1% positive cells, 1+=1–24% positive cells, 2+=25–75% positive cells, 3+=>75% positive cells. ND=not determined.